2023 Global Therapeutic Drug Monitoring (TDM) Market Assessment for 28 Assays in US, Europe, Japan-2022 Supplier Shares and 2022-2027 Segment Forecasts by Test and Country, Competitive Intelligence, Emerging Technologies, Instrumentation and Opportunities for Suppliers
![](/report_cover/2215/2023-global-therapeutic-drug-monitoring-tdm-market-assessment-4-28-assays-in-us-europe-japan-2022-supplier-shares-n-2022-2027-segment-forecasts_en.gif)
This unique report from LeadingMarketResearch.com provides information and analysis not available from any other published source.
The report is available by country, section, and can be customized to specific information needs and budget.
This new report provides analysis of the global therapeutic drug monitoring testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and strategic profiles of leading suppliers.
The report provides test volume and sales forecasts by country and market segment for the following assays:
Amikacin, Apixaban, Argatroban, Betrixaban, Carbamazepine, Cyclosporin, Dabigatran, Digoxin, Edoxaban, Everolimus, Fluindione, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Rivaroxaban, Sirolimus, Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid, Vancomycin, and Warfarin.
During the next decade, the TDM market will undergo significant transformation. These changes will be caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments will start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others.
This report is a unique worldwide market and technology assessment designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and developed effective strategic responses. The study provides five-year forecasts for major TDM assays; compares features of leading analyzers; and profiles key competitors.
The report is available by country, section, and can be customized to specific information needs and budget.
This new report provides analysis of the global therapeutic drug monitoring testing market, including emerging tests, technologies, instrumentation, sales forecasts by country, market shares, and strategic profiles of leading suppliers.
The report provides test volume and sales forecasts by country and market segment for the following assays:
Amikacin, Apixaban, Argatroban, Betrixaban, Carbamazepine, Cyclosporin, Dabigatran, Digoxin, Edoxaban, Everolimus, Fluindione, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Rivaroxaban, Sirolimus, Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid, Vancomycin, and Warfarin.
During the next decade, the TDM market will undergo significant transformation. These changes will be caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments will start resembling commodity markets, where product positioning and cost per test are more critical than underlying technology. This evolving marketplace will create exciting opportunities for a variety of new instruments, reagent systems, and auxiliary products, such as specimen preparation devices, controls, calibrators and others.
This report is a unique worldwide market and technology assessment designed to help current suppliers and potential market entrants identify and evaluate emerging opportunities and developed effective strategic responses. The study provides five-year forecasts for major TDM assays; compares features of leading analyzers; and profiles key competitors.
INTRODUCTION
WORLDW IDE MARKET AND TECHNOLOGY OVERVIEW
A. Major Therapeutic Drug Monitoring Tests
The report provides segment test volume and sales forecasts for the following tests:
Amikacin, Apixaban, Argatroban, Betrixaban, Carbamazepine, Cyclosporin, Dabigatran, Digoxin, Edoxaban, Everolimus, Fluindione, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Rivaroxaban, Sirolimus, Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid, Vancomycin and Warfarin.
B. Instrumentation Review: Operating characteristics and features of high-, medium-, and low-volume/POC analyzers manufactured by Abaxis, Abbott, Alfa
W assermann, AMS, Awareness Technologies, Beckman Coulter, Binding Site, bioMerieux, Carolina Chemistries, DiaSorin, Grifols, Horiba, Medica, Nova Biomedical, Ortho-Clinical Diagnostics, Polymedco, Randox, Roche, Siemens Healthineers, Tosoh, Vital Diagnostics and other suppliers.
C. Major In Vitro Diagnostic Technologies And Their Potential Applications
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
a. Technological Principle
b. Chemiluminescence
c. Enzyme Immunoassays
Overview
ELISA
EMIT
Electrochemical
d. Radioimmunoassays (RIA)
e. Immunoprecipitation
f. Affinity Chromatography
3. Tandem Mass Spec
4. IT and Automation
5. Dry Chemistry
6. Biosensors
Test Volume and Sales Forecasts by Assay and Market Segment, And Major Supplier Market Shares
ALTERNATIVE MARKET PENETRATION STRATEGIES
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
1. Marketing Approaches
2. Product Complexity
3. Customer Preference
4. Established Suppliers
5. Emerging Suppliers
6. Major Types of Distributors
7. Market Segmentation
POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
COMPETITIVE ASSESSMENTS
Abbott
Agilent Technologies
Beckman Coulter/Danaher
bioMerieux
Bio-Rad
DiaSorin
Eiken Chemical
Fujifilm Wako
Fujirebio
Grifols
IL/Werfen
Kyowa Medex
PerkinElmer
Quest Diagnostics
QuidelOrtho
Roche
Siemens Healthineers
Sysmex
Thermo Fisher
Tosoh
WORLDW IDE MARKET AND TECHNOLOGY OVERVIEW
A. Major Therapeutic Drug Monitoring Tests
The report provides segment test volume and sales forecasts for the following tests:
Amikacin, Apixaban, Argatroban, Betrixaban, Carbamazepine, Cyclosporin, Dabigatran, Digoxin, Edoxaban, Everolimus, Fluindione, Gentamicin, Levetiracetam, Lithium, Methotrexate, NAPA/Procainamide, Phenobarbital, Phenytoin, Quinidine, Rivaroxaban, Sirolimus, Tacrolimus, Theophylline, Tobramycin, Topirimate, Valproic Acid, Vancomycin and Warfarin.
B. Instrumentation Review: Operating characteristics and features of high-, medium-, and low-volume/POC analyzers manufactured by Abaxis, Abbott, Alfa
W assermann, AMS, Awareness Technologies, Beckman Coulter, Binding Site, bioMerieux, Carolina Chemistries, DiaSorin, Grifols, Horiba, Medica, Nova Biomedical, Ortho-Clinical Diagnostics, Polymedco, Randox, Roche, Siemens Healthineers, Tosoh, Vital Diagnostics and other suppliers.
C. Major In Vitro Diagnostic Technologies And Their Potential Applications
1. Monoclonal and Polyclonal Antibodies
2. Immunoassays
a. Technological Principle
b. Chemiluminescence
c. Enzyme Immunoassays
Overview
ELISA
EMIT
Electrochemical
d. Radioimmunoassays (RIA)
e. Immunoprecipitation
f. Affinity Chromatography
3. Tandem Mass Spec
4. IT and Automation
5. Dry Chemistry
6. Biosensors
Test Volume and Sales Forecasts by Assay and Market Segment, And Major Supplier Market Shares
ALTERNATIVE MARKET PENETRATION STRATEGIES
A. Internal Development
B. Collaborative Arrangements
C. University Contracts
D. Distribution Strategies for Decentralized Testing Markets
1. Marketing Approaches
2. Product Complexity
3. Customer Preference
4. Established Suppliers
5. Emerging Suppliers
6. Major Types of Distributors
7. Market Segmentation
POTENTIAL MARKET ENTRY BARRIERS AND RISKS
A. Market Maturity
B. Cost Containment
C. Competition
D. Technological Edge and Limitations
E. Patent Protection
F. Regulatory Constraints
G. Decentralized Testing Market Challenges
COMPETITIVE ASSESSMENTS
Abbott
Agilent Technologies
Beckman Coulter/Danaher
bioMerieux
Bio-Rad
DiaSorin
Eiken Chemical
Fujifilm Wako
Fujirebio
Grifols
IL/Werfen
Kyowa Medex
PerkinElmer
Quest Diagnostics
QuidelOrtho
Roche
Siemens Healthineers
Sysmex
Thermo Fisher
Tosoh